Within 10 y after primary curative-intent treatment for prostate cancer with radiation therapy (RT) or radical prostatectomy (RP), approximately 40% of patients will develop biochemical recurrence (BCR) (1,2), characterized by an increasing serum prostate-specific antigen (PSA) level. The gene discussed is KLK3; the disease is prostate carcinoma.